40254-90-8

Cyclin-dependent kinases (Cdks) are key regulators of cell cycle progression and are therefore promising targets for cancer therapy. Cdk1/5 Inhibitor is a pyrazolo [3,4-b] quioxaline that inhibits Cdk1/cyclin B and Cdk5/p25 (IC₅₀s = 600 and 400 nM, respectively). It less potently inhibits GSK3β (IC₅₀ = 1 μM) and does not block Cdc25 activity. This compound is used to help define the roles of Cdk1 and Cdk5 in various signaling pathways.

Cyclin-dependent kinases (CDKs) are protein kinases and involved with the regulation of the cell cycle. NSC 693868 is an inhibitor of Cdk1/cyclin B and Cdk5/p25.?Small molecules that target these protein kinases are valuable tools for investigating cellular signaling pathways and are potential therapeutic agents.

ChEBI: 2H-pyrazolo[4,3-b]quinoxalin-3-amine is a quinoxaline derivative.

Inhibitor of cyclin-dependent kinases (cdks) and glycogen synthase kinase-3 (GSK-3). IC 50 values are 0.6, 0.4 and 1 μ M for cdk1/cyclin B, cdk5/p25 and GSK-3 respectively.

Store at -20°C